Stockreport

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting [Yahoo! Finance]

Upstream Bio, Inc.  (UPB) 
PDF Upstream Bio – Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p – Secondary endpoints also provided strong efficacy data in new [Read more]